drugset / Trial / NCT06822166

Drug Interactions Trial of Methoxyethyl Etomidate Hydrochloride

NCT06822166

Phase 1 Completed 68 enrolled Ahon Pharmaceutical Co., Ltd.
Non-randomizedCrossoverOpen-labelOther

Summary

Sixty-eight healthy subjects were divided into three sequences: A, B and C. The effects of CYP2C19 inhibitor fluconazole and inducer rifampicin on ET-26-HCl injection were evaluated, and the effects of ET-26-HCl injection on pharmacokinetics of omeprazole and midazolam were evaluated.

Timeline

Start
2023-12-04
Primary completion
2024-01-23
Completion
2024-01-23

Drugs

EvaluationDrugModalityDoseRoute
Subject ET-26 Unknown 0.8 mg/kg
Subject Fluconazole Small molecule 200 mg
Subject Midazolam Small molecule 0.05 mg/kg Intravenous
Subject Omeprazole Other / unclassified 20 mg
Subject Rifampin Small molecule 600 mg

Indications

No indication recorded.